Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT01702311 · ClinicalTrials.gov registry record · NA

Point-of-Care Glucose Testing and Insulin Supplementation

A NA study, sponsored by Emory University.

Completed
Registry status
NA
Development phase
235
Enrollment target

NCT01702311 is a NA study that has completed, run by Emory University. The registered enrollment target is 235 participants.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT01702311, a NA study, has completed, sponsored by Emory University.

COMPLETED
Registry status
NA
Development phase
235 participants
Enrollment target

Study Summary

Capillary point-of-care (POC) testing is advocated as a valuable aid in the management of diabetes and hyperglycemia in the hospital setting. POC testing aims at collecting information on BG levels at different time points during the day in order to assess glycemic control and to guide insulin adjustment/correction doses. Although POC testing provides insights into day-to-day excursions in BG levels, bedtime BG testing triggers the use of insulin supplements that may result in increased frequency of hypoglycemia and is expensive with an estimated annual cost in hospitals of several hundreds of millions of dollars in the U.S. Accordingly, this pilot study aims to assess the utility of POC and insulin supplementation (correction doses) at bedtime in improving glycemic control and in preventing hypoglycemia in non-ICU patients with type 2 diabetes mellitus (T2DM). A total of 250 non-ICU medical and surgical patients treated with basal bolus regimen will undergo POC testing before meals and bedtime (standard of care) and half of the patients will receive insulin correction doses at bedtime for BG \> 140 mg/dL following a sliding scale protocol, while the other half will be followed without insulin supplementation at bedtime except for extreme hyperglycemia (BG \> 350 mg/dl). Patients will be recruited at Emory University Hospital and Grady Memorial Hospital.

Interventions

  • DRUG Bedtime insulin Aspart (Novolog)

Trial Details

FieldValue
Enrollment Target 235 participants
Start Date 2012-05
Est. Completion 2013-12
Phase NA

Sponsor

Emory University

1,208 total trials

What the Registry Record Tells You About NCT01702311

The ClinicalTrials.gov registry entry for NCT01702311 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 235 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Emory University, which has 1,208 total studies on file at ClinicalTrials.gov.

The record links to 0 conditions, and to 1 intervention - of which Bedtime insulin Aspart (Novolog) is the first listed.

NCT01702311 reports 0 study locations.

Frequently Asked Questions

What is clinical trial NCT01702311 about?

NCT01702311 is a clinical study titled "Point-of-Care Glucose Testing and Insulin Supplementation". Capillary point-of-care (POC) testing is advocated as a valuable aid in the management of diabetes and hyperglycemia in the hospital setting. POC testing aims at collecting information on BG levels at different time points during the day in order to assess glycemic control and to guide insulin adjus...

What is the current status of trial NCT01702311?

This trial is currently completed. It is a NA study. The enrollment target is 235 participants. The study started on 2012-05. Estimated completion is 2013-12.

What interventions are being tested in trial NCT01702311?

The interventions under investigation include: Bedtime insulin Aspart (Novolog) (DRUG).

Who is sponsoring clinical trial NCT01702311?

This trial is sponsored by Emory University, which has 1,208 total clinical trials registered on ClinicalTrials.gov.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.